Close X
Attorney Spotlight

What colorful method does Claire Miley use to keep up with the latest healthcare regulations as they relate to proposed transactions? Find out more>

Search

Close X

Experience

Search our Experience

Experience Spotlight

On December 1, 2016, Parker Hannifin Corporation and CLARCOR Inc. announced that the companies have entered into a definitive agreement under which Parker will acquire CLARCOR for approximately $4.3 billion in cash, including the assumption of net debt. The transaction has been unanimously approved by the board of directors of each company. Upon closing of the transaction, expected to be completed by or during the first quarter of Parker’s fiscal year 2018, CLARCOR will be combined with Parker’s Filtration Group to form a leading and diverse global filtration business. Bass, Berry & Sims has served CLARCOR as primary corporate and securities counsel for 10 years and served as lead counsel on this transaction. Read more here.

CLARCOR
Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Securities Law Exchange BlogSecurities Law Exchange blog offers insight on the latest legal and regulatory developments affecting publicly traded companies. It focuses on a wide variety of topics including regulation and reporting updates, public company advisory topics, IPO readiness and exchange updates including IPO announcements, M&A trends and deal news.

Read More >

Attorney Spotlight: Julia Tamulis

November 6, 2014

Julia TamulisTell us about your practice.

I prepare, file and argue appeals of Medicare reimbursement denials on behalf of hospitals. Recently, I have assisted hospitals in preparing for participation in CMS' settlement program designed to alleviate the tremendous backlog of Medicare appeals, particularly at the ALJ level. Additionally, as part of the firm's healthcare fraud task force, I assist with the process of responding to government healthcare fraud investigations and provide related healthcare regulatory analysis.

What are some trends you are seeing related to the legal industry or in the industry in which you practice?

In the Medicare appeals space, providers are struggling with the practical implications of the massive delays in the appeals system in terms of employee resources and finances. In anticipation of the October 31, 2014 deadline for hospitals with appeals of inpatient status claims to settle with CMS, hospitals are analyzing the volume, strength, and value of such claims against the benefits of settlement. In the healthcare fraud area, the government's recent actions and pronouncements indicate an increased use of non-monetary enforcement tactics, including robust corporate integrity agreements, to encourage industry compliance.

How did your work at HHS prepare you for the work you currently are doing?

While at HHS, I drafted decisions in Medicare appeals under Medicare Part A and B for the Medicare Operations Division of the Departmental Appeals Board, the highest level of administrative review within HHS. This experience gave me a solid introduction to Medicare, requiring me to spend most of my time immersed in the Medicare regulations. Beyond developing my writing skills, my time at HHS afforded me an opportunity to spend all of my working time analyzing healthcare regulations and applying them to different fact scenarios, which has proved an excellent background to both my appeals work and my healthcare fraud investigation work.


Related Professionals

Related Services

Notice

Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.